10 min read · updated 2026-08-21
Peptide Regulatory Status: What the 2026 FDA Actions Did and Did Not Change
The 503A framework, the April removals, the July advisory vote, and why the coverage of all three has been consistently wrong.
The framework these actions operate within
Section 503A of the Federal Food, Drug, and Cosmetic Act governs which bulk drug substances state-licensed compounding pharmacies may use when preparing a preparation against an individual prescription. While the FDA evaluates a nominated substance it sits in one of three interim categories. Category 1 covers substances under evaluation where the agency does not intend enforcement action during review. Category 2 covers substances the agency has identified as raising significant safety concerns, which in practice blocks compounding. Category 3 covers substances nominated without adequate supporting information. None of this framework governs research supply, and none of it constitutes drug approval — a separate process requiring demonstration of safety and effectiveness for a specific indication.
What happened in April 2026
On 15 April 2026 the FDA published notice removing twelve peptide substances from Category 2 of the 503A bulk drug substances list, effective 22 April. The twelve were BPC-157, LL-37, DiHexa acetate, emideltide (DSIP), epitalon, injectable GHK-Cu, KPV, PEG-MGF, melanotan II, MOTS-c, semax, and TB-500. The mechanism matters and was widely misreported: the substances came off Category 2 because the parties who had nominated them withdrew those nominations, not because the agency made a finding that they were safe to compound. Removal from Category 2 lifts a prohibition designation. It does not place a substance on the affirmative 503A list, which requires a separate process.
What the July 2026 advisory vote did
The Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to consider whether seven of the removed peptides should be added to the affirmative 503A list. It recommended six — BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon — and recommended against emideltide. The votes were close and, unusually, went against the written recommendation of FDA scientific staff, who had opposed adding any of the seven. The committee considered both free base and acetate forms. A second meeting covering additional substances is expected in February 2027, with injectable GHK-Cu on a separate track.
What none of it changed
An advisory committee recommendation is not a decision. The FDA is not bound by it, and formal addition to the 503A list requires notice-and-comment rulemaking — a proposed rule, a comment period, review, and a final rule. As of August 2026 no such rule has been finalised for any of these substances, none has been added to the affirmative list, and none is an FDA-approved drug. The practical position is unchanged from before April: these are unapproved substances, not authorised for compounding under a settled framework, and not approved for human use in any form.
Why the coverage has been wrong
Three distinct things are routinely collapsed into one. Removal from a prohibition list, recommendation for an authorisation list, and drug approval are separate events with separate legal consequences, and only the first two have occurred. Headlines describing the April action as the FDA clearing or approving these compounds described something that did not happen; the same pattern repeated after July. The underlying reason the error persists is that each step sounds like progress toward availability, and the distance between an advisory recommendation and a final rule is not obvious to a general reader. Anyone relying on these reports to conclude that regulatory status has materially changed has been misled.
What this means for research supply
Nothing in either action alters the research use only designation or the obligations attached to it. The 503A framework governs pharmacy compounding for individual patients under prescription — a different activity, under a different statutory provision, from the supply of material for laboratory investigation. Compounds discussed in this guide remain unapproved for human use regardless of where they sit in the compounding review. A supplier describing these actions as a change in the status of research material is describing something that did not occur.
Frequently asked
Did the FDA approve BPC-157 in 2026?
No. The April 2026 action removed it from Category 2 of the 503A compounding list, and the July advisory committee recommended it for the affirmative list. Neither is drug approval, which is a separate process. BPC-157 remains an unapproved substance.
Can compounding pharmacies prepare these peptides now?
Not under a settled framework. The advisory committee recommendation is not binding, and formal addition to the 503A list requires notice-and-comment rulemaking that has not concluded as of August 2026.
Why were the peptides removed from Category 2?
Because the parties who nominated them withdrew those nominations, which is a procedural event. The removal was not a finding by the agency that the substances are safe to compound.
Are these compounds banned in competitive sport?
Many are. The World Anti-Doping Agency maintains a prohibited list that includes several growth factor and secretagogue classes, and it is updated annually. Athletes subject to testing should check the current list directly rather than rely on a supplier summary.
See the practice, not just the principle
Every lot we release is published in full — assay, method, and measured result — and the record stays online after the lot sells out.
Open the COA library